Artax Biopharma
  • Resources
  • Partners
  • Media
  • Contact us
  • Our Approach
  • Our Patients
  • About Artax
  • Our Pipeline and Progress

Scientific Publications

  • Feature Jan 22, 2025

    Artax Biopharma achieves clinical validation of first-in-class, oral,  Nck modulator AX-158 for autoimmune disease in phase 2a study

    Cambridge, MA, January 22, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the…
    • Scientific Publication
    • Press Releases
    • Media
    • Scientific Publications
    Nov 20, 2024

    First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T cell Receptor Signal Modulator AX-158

    D. Scott Batty presented the first-in-human Phase 1 trial results of AX-158 at ACR Convergence…
    • Scientific Publications
    Nov 20, 2024

    TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases

    Christopher VanDeusen presented data on the mechanism of action of AX-158, a first-in-class Nck modulator, at…
    • Scientific Publications
    May 30, 2022

    Impacts of TCR-Nck Interaction Inhibitors on T Cell Activation Driven By Mixed Lymphocyte Reactions

    Dwyer et al., (2022) Conference on the Science of Dissemination and Implementation in Health
    • Scientific Publications
    Aug 12, 2019

    The TCR is an allosterically regulated macromolecular machinery changing its conformation while working

    Schamel W., et al (2019), Immunological Reviews
    • Scientific Publications
    Jun 9, 2018

    Anti-CD3 Fab Fragments Enhance Tumor Killing by Human γδ T Cells Independent of Nck Recruitment to the γδ T Cell Antigen Receptor

    Juraske, C. et. al., (2018), Frontiers in Immunology
    • Scientific Publications
    May 20, 2016

    First-in-class inhibitor of the T Cell receptor for the treatment of autoimmune diseases

    Borrato A., et al. (2016), Science Translational Medicine
    • Scientific Publications
    Jan 1, 2016

    Nck Binds to the T Cell Antigen Receptor Using Its SH3.1 and SH2 Domains in a Cooperative Manner, Promoting TCR Functioning

    Paensuwan, P. et. al. (2016), The Journal of Immunology
    • Scientific Publications
    Mar 1, 2014

    Relevance of Nck–CD3ε Interaction for T Cell Activation In Vivo

    Borrato A., et al. (2014), The Journal of Immunology
    • Scientific Publications
    Jun 28, 2002

    Recruitment of Nck by CD3ϵ Reveals a Ligand-Induced Conformational Change Essential for T Cell Receptor Signaling and Synapse Formation

    Gil C., et al. (2002), Cell

1 in 10 individuals is affected by autoimmune disease –
join our mission to treat them

Interested in learning more?

Ask us a question – the Artax team can help you

Get in touch
Clinical trials participation

Help us evaluate Nck modulation in clinical trials

About clinical trials
Partner with Artax

Explore Nck modulators for autoimmune conditions

About partnering with Artax

© Artax Biopharma. All Rights Reserved.

Terms of Use | Privacy Policy

Artax Biopharma
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}